id	sid	tid	token	lemma	pos
dhrp-31	1	1	2021	2021	NUM
dhrp-31	1	2	,	,	PUNCT
dhrp-31	1	3	vol	vol	NOUN
dhrp-31	1	4	.	.	NOUN
dhrp-31	1	5	1	1	NUM
dhrp-31	1	6	(	(	PUNCT
dhrp-31	1	7	s5	s5	NOUN
dhrp-31	1	8	)	)	PUNCT
dhrp-31	1	9	1	1	NUM
dhrp-31	1	10	-	-	SYM
dhrp-31	1	11	3	3	NUM
dhrp-31	1	12	https://doi.org/10.47488/dhrp.v1is5.31	https://doi.org/10.47488/dhrp.v1is5.31	NOUN
dhrp-31	1	13	http://dhrproceedings.org	http://dhrproceedings.org	PROPN
dhrp-31	1	14	1	1	NUM
dhrp-31	1	15	©	©	PROPN
dhrp-31	1	16	dhr	dhr	PROPN
dhrp-31	1	17	health	health	PROPN
dhrp-31	1	18	institute	institute	PROPN
dhrp-31	1	19	for	for	ADP
dhrp-31	1	20	research	research	NOUN
dhrp-31	1	21	and	and	CCONJ
dhrp-31	1	22	development	development	NOUN
dhrp-31	1	23	editorial	editorial	NOUN
dhrp-31	1	24	is	be	AUX
dhrp-31	1	25	there	there	PRON
dhrp-31	1	26	any	any	DET
dhrp-31	1	27	advantage	advantage	NOUN
dhrp-31	1	28	of	of	ADP
dhrp-31	1	29	using	use	VERB
dhrp-31	1	30	polyclonal	polyclonal	NOUN
dhrp-31	1	31	vs.	vs.	X
dhrp-31	1	32	monoclonal	monoclonal	NOUN
dhrp-31	1	33	antibodies	antibody	NOUN
dhrp-31	1	34	for	for	ADP
dhrp-31	1	35	passive	passive	ADJ
dhrp-31	1	36	enhancement	enhancement	NOUN
dhrp-31	1	37	of	of	ADP
dhrp-31	1	38	immunity	immunity	NOUN
dhrp-31	1	39	in	in	ADP
dhrp-31	1	40	patients	patient	NOUN
dhrp-31	1	41	with	with	ADP
dhrp-31	1	42	covid-19	covid-19	PROPN
dhrp-31	1	43	?	?	PUNCT
dhrp-31	2	1	on	on	ADP
dhrp-31	2	2	november	november	PROPN
dhrp-31	2	3	08	08	NUM
dhrp-31	2	4	,	,	PUNCT
dhrp-31	2	5	2020	2020	NUM
dhrp-31	2	6	,	,	PUNCT
dhrp-31	2	7	the	the	DET
dhrp-31	2	8	us	us	PROPN
dhrp-31	2	9	food	food	PROPN
dhrp-31	2	10	&	&	CCONJ
dhrp-31	2	11	drug	drug	PROPN
dhrp-31	2	12	administration	administration	PROPN
dhrp-31	2	13	(	(	PUNCT
dhrp-31	2	14	fda	fda	PROPN
dhrp-31	2	15	)	)	PUNCT
dhrp-31	2	16	approved	approve	VERB
dhrp-31	2	17	the	the	DET
dhrp-31	2	18	use	use	NOUN
dhrp-31	2	19	of	of	ADP
dhrp-31	2	20	first	first	ADJ
dhrp-31	2	21	monoclonal	monoclonal	NOUN
dhrp-31	2	22	antibody	antibody	NOUN
dhrp-31	2	23	–	–	PUNCT
dhrp-31	2	24	bamlanivimab	bamlanivimab	NOUN
dhrp-31	2	25	(	(	PUNCT
dhrp-31	2	26	lycov555	lycov555	PROPN
dhrp-31	2	27	;	;	PUNCT
dhrp-31	2	28	eli	eli	PROPN
dhrp-31	2	29	lilly	lilly	PROPN
dhrp-31	2	30	&	&	CCONJ
dhrp-31	2	31	company	company	PROPN
dhrp-31	2	32	)	)	PUNCT
dhrp-31	2	33	for	for	ADP
dhrp-31	2	34	the	the	DET
dhrp-31	2	35	treatment	treatment	NOUN
dhrp-31	2	36	of	of	ADP
dhrp-31	2	37	high	high	ADJ
dhrp-31	2	38	-	-	PUNCT
dhrp-31	2	39	risk	risk	NOUN
dhrp-31	2	40	patients	patient	NOUN
dhrp-31	2	41	with	with	ADP
dhrp-31	2	42	mild	mild	ADJ
dhrp-31	2	43	-	-	PUNCT
dhrp-31	2	44	moderate	moderate	ADJ
dhrp-31	2	45	sars	sar	NOUN
dhrp-31	2	46	-	-	PUNCT
dhrp-31	2	47	cov2	cov2	PROPN
dhrp-31	2	48	infection	infection	NOUN
dhrp-31	2	49	(	(	PUNCT
dhrp-31	2	50	1	1	NUM
dhrp-31	2	51	)	)	PUNCT
dhrp-31	2	52	.	.	PUNCT
dhrp-31	3	1	subsequently	subsequently	ADV
dhrp-31	3	2	,	,	PUNCT
dhrp-31	3	3	on	on	ADP
dhrp-31	3	4	november	november	PROPN
dhrp-31	3	5	23	23	NUM
dhrp-31	3	6	,	,	PUNCT
dhrp-31	3	7	2020	2020	NUM
dhrp-31	3	8	,	,	PUNCT
dhrp-31	3	9	fda	fda	PROPN
dhrp-31	3	10	approved	approve	VERB
dhrp-31	3	11	another	another	DET
dhrp-31	3	12	cocktail	cocktail	NOUN
dhrp-31	3	13	of	of	ADP
dhrp-31	3	14	monoclonal	monoclonal	NOUN
dhrp-31	3	15	antibodies	antibody	NOUN
dhrp-31	3	16	–	–	PUNCT
dhrp-31	3	17	casirivimab	casirivimab	NOUN
dhrp-31	3	18	+	+	CCONJ
dhrp-31	3	19	imdevimab	imdevimab	NOUN
dhrp-31	3	20	(	(	PUNCT
dhrp-31	3	21	regen	regen	NOUN
dhrp-31	3	22	-	-	PUNCT
dhrp-31	3	23	cov	cov	NOUN
dhrp-31	3	24	;	;	PUNCT
dhrp-31	3	25	regeneron	regeneron	NOUN
dhrp-31	3	26	pharmaceuticals	pharmaceutical	NOUN
dhrp-31	3	27	)	)	PUNCT
dhrp-31	3	28	for	for	ADP
dhrp-31	3	29	use	use	NOUN
dhrp-31	3	30	in	in	ADP
dhrp-31	3	31	a	a	DET
dhrp-31	3	32	similar	similar	ADJ
dhrp-31	3	33	cohort	cohort	NOUN
dhrp-31	3	34	of	of	ADP
dhrp-31	3	35	high	high	ADJ
dhrp-31	3	36	-	-	PUNCT
dhrp-31	3	37	risk	risk	NOUN
dhrp-31	3	38	patients	patient	NOUN
dhrp-31	3	39	with	with	ADP
dhrp-31	3	40	mild	mild	ADJ
dhrp-31	3	41	-	-	PUNCT
dhrp-31	3	42	moderate	moderate	ADJ
dhrp-31	3	43	covid-19	covid-19	PROPN
dhrp-31	3	44	.	.	PUNCT
dhrp-31	4	1	since	since	SCONJ
dhrp-31	4	2	the	the	DET
dhrp-31	4	3	initial	initial	ADJ
dhrp-31	4	4	emergency	emergency	NOUN
dhrp-31	4	5	use	use	NOUN
dhrp-31	4	6	authorizations	authorization	NOUN
dhrp-31	4	7	(	(	PUNCT
dhrp-31	4	8	eua	eua	PROPN
dhrp-31	4	9	)	)	PUNCT
dhrp-31	4	10	,	,	PUNCT
dhrp-31	4	11	fda	fda	PROPN
dhrp-31	4	12	has	have	AUX
dhrp-31	4	13	made	make	VERB
dhrp-31	4	14	numerous	numerous	ADJ
dhrp-31	4	15	modifications	modification	NOUN
dhrp-31	4	16	/	/	SYM
dhrp-31	4	17	amendments	amendment	NOUN
dhrp-31	4	18	including	include	VERB
dhrp-31	4	19	revoking	revoke	VERB
dhrp-31	4	20	the	the	DET
dhrp-31	4	21	authorization	authorization	NOUN
dhrp-31	4	22	for	for	ADP
dhrp-31	4	23	monotherapy	monotherapy	NOUN
dhrp-31	4	24	with	with	ADP
dhrp-31	4	25	bamlanivimab	bamlanivimab	NOUN
dhrp-31	4	26	(	(	PUNCT
dhrp-31	4	27	3	3	NUM
dhrp-31	4	28	)	)	PUNCT
dhrp-31	4	29	;	;	PUNCT
dhrp-31	4	30	addition	addition	NOUN
dhrp-31	4	31	of	of	ADP
dhrp-31	4	32	etesevimab	etesevimab	NOUN
dhrp-31	4	33	to	to	PART
dhrp-31	4	34	bamlanivimab	bamlanivimab	VERB
dhrp-31	4	35	monotherapy	monotherapy	NOUN
dhrp-31	4	36	;	;	PUNCT
dhrp-31	4	37	and	and	CCONJ
dhrp-31	4	38	authorization	authorization	NOUN
dhrp-31	4	39	of	of	ADP
dhrp-31	4	40	another	another	DET
dhrp-31	4	41	monoclonal	monoclonal	NOUN
dhrp-31	4	42	antibody	antibody	NOUN
dhrp-31	4	43	–	–	PUNCT
dhrp-31	4	44	sotrovimab	sotrovimab	NOUN
dhrp-31	4	45	(	(	PUNCT
dhrp-31	4	46	xevudy	xevudy	PROPN
dhrp-31	4	47	;	;	PUNCT
dhrp-31	4	48	glaxo	glaxo	PROPN
dhrp-31	4	49	,	,	PUNCT
dhrp-31	4	50	smith	smith	PROPN
dhrp-31	4	51	&	&	CCONJ
dhrp-31	4	52	kline	kline	PROPN
dhrp-31	4	53	)	)	PUNCT
dhrp-31	4	54	(	(	PUNCT
dhrp-31	4	55	4	4	NUM
dhrp-31	4	56	)	)	PUNCT
dhrp-31	4	57	,	,	PUNCT
dhrp-31	4	58	the	the	DET
dhrp-31	4	59	primary	primary	ADJ
dhrp-31	4	60	objective	objective	NOUN
dhrp-31	4	61	of	of	ADP
dhrp-31	4	62	these	these	DET
dhrp-31	4	63	emergency	emergency	NOUN
dhrp-31	4	64	authorizations	authorization	NOUN
dhrp-31	4	65	was	be	AUX
dhrp-31	4	66	to	to	PART
dhrp-31	4	67	treat	treat	VERB
dhrp-31	4	68	patients	patient	NOUN
dhrp-31	4	69	early	early	ADV
dhrp-31	4	70	in	in	ADP
dhrp-31	4	71	the	the	DET
dhrp-31	4	72	course	course	NOUN
dhrp-31	4	73	of	of	ADP
dhrp-31	4	74	the	the	DET
dhrp-31	4	75	disease	disease	NOUN
dhrp-31	4	76	in	in	ADP
dhrp-31	4	77	an	an	DET
dhrp-31	4	78	non	non	ADJ
dhrp-31	4	79	-	-	ADJ
dhrp-31	4	80	hospitalized	hospitalize	VERB
dhrp-31	4	81	setting	set	VERB
dhrp-31	4	82	thus	thus	ADV
dhrp-31	4	83	mitigating	mitigate	VERB
dhrp-31	4	84	the	the	DET
dhrp-31	4	85	progression	progression	NOUN
dhrp-31	4	86	of	of	ADP
dhrp-31	4	87	covid-19	covid-19	PROPN
dhrp-31	4	88	to	to	ADP
dhrp-31	4	89	a	a	DET
dhrp-31	4	90	more	more	ADV
dhrp-31	4	91	severe	severe	ADJ
dhrp-31	4	92	stage	stage	NOUN
dhrp-31	4	93	that	that	PRON
dhrp-31	4	94	would	would	AUX
dhrp-31	4	95	necessitate	necessitate	VERB
dhrp-31	4	96	hospitalization	hospitalization	NOUN
dhrp-31	4	97	.	.	PUNCT
dhrp-31	5	1	with	with	ADP
dhrp-31	5	2	the	the	DET
dhrp-31	5	3	availability	availability	NOUN
dhrp-31	5	4	of	of	ADP
dhrp-31	5	5	these	these	DET
dhrp-31	5	6	monoclonal	monoclonal	NOUN
dhrp-31	5	7	antibodies	antibodie	VERB
dhrp-31	5	8	,	,	PUNCT
dhrp-31	5	9	we	we	PRON
dhrp-31	5	10	at	at	ADP
dhrp-31	5	11	dhr	dhr	PROPN
dhrp-31	5	12	health	health	PROPN
dhrp-31	5	13	proceeded	proceed	VERB
dhrp-31	5	14	to	to	PART
dhrp-31	5	15	obtain	obtain	VERB
dhrp-31	5	16	approval	approval	NOUN
dhrp-31	5	17	of	of	ADP
dhrp-31	5	18	a	a	DET
dhrp-31	5	19	prospective	prospective	ADJ
dhrp-31	5	20	study	study	NOUN
dhrp-31	5	21	from	from	ADP
dhrp-31	5	22	the	the	DET
dhrp-31	5	23	dhr	dhr	PROPN
dhrp-31	5	24	health	health	PROPN
dhrp-31	5	25	institute	institute	PROPN
dhrp-31	5	26	for	for	ADP
dhrp-31	5	27	research	research	PROPN
dhrp-31	5	28	&	&	CCONJ
dhrp-31	5	29	development	development	PROPN
dhrp-31	5	30	institutional	institutional	PROPN
dhrp-31	5	31	review	review	PROPN
dhrp-31	5	32	board	board	NOUN
dhrp-31	5	33	to	to	PART
dhrp-31	5	34	treat	treat	VERB
dhrp-31	5	35	high	high	ADJ
dhrp-31	5	36	-	-	PUNCT
dhrp-31	5	37	risk	risk	NOUN
dhrp-31	5	38	patients	patient	NOUN
dhrp-31	5	39	with	with	ADP
dhrp-31	5	40	mild	mild	ADJ
dhrp-31	5	41	-	-	PUNCT
dhrp-31	5	42	moderate	moderate	ADJ
dhrp-31	5	43	covid-19	covid-19	PROPN
dhrp-31	5	44	.	.	PUNCT
dhrp-31	6	1	the	the	DET
dhrp-31	6	2	first	first	ADJ
dhrp-31	6	3	patient	patient	NOUN
dhrp-31	6	4	was	be	AUX
dhrp-31	6	5	treated	treat	VERB
dhrp-31	6	6	on	on	ADP
dhrp-31	6	7	november	november	PROPN
dhrp-31	6	8	25	25	NUM
dhrp-31	6	9	,	,	PUNCT
dhrp-31	6	10	2020	2020	NUM
dhrp-31	6	11	,	,	PUNCT
dhrp-31	6	12	and	and	CCONJ
dhrp-31	6	13	since	since	SCONJ
dhrp-31	6	14	then	then	ADV
dhrp-31	6	15	,	,	PUNCT
dhrp-31	6	16	we	we	PRON
dhrp-31	6	17	have	have	AUX
dhrp-31	6	18	infused	infuse	VERB
dhrp-31	6	19	anti	anti	ADJ
dhrp-31	6	20	-	-	ADJ
dhrp-31	6	21	sars	sars	ADJ
dhrp-31	6	22	-	-	PUNCT
dhrp-31	6	23	cov-2	cov-2	NOUN
dhrp-31	6	24	monoclonal	monoclonal	NOUN
dhrp-31	6	25	antibodies	antibodie	VERB
dhrp-31	6	26	in	in	ADP
dhrp-31	6	27	over	over	ADP
dhrp-31	6	28	580	580	NUM
dhrp-31	6	29	patients	patient	NOUN
dhrp-31	6	30	with	with	ADP
dhrp-31	6	31	very	very	ADV
dhrp-31	6	32	satisfactory	satisfactory	ADJ
dhrp-31	6	33	outcomes	outcome	NOUN
dhrp-31	6	34	.	.	PUNCT
dhrp-31	7	1	this	this	PRON
dhrp-31	7	2	included	include	VERB
dhrp-31	7	3	both	both	DET
dhrp-31	7	4	patients	patient	NOUN
dhrp-31	7	5	who	who	PRON
dhrp-31	7	6	had	have	VERB
dhrp-31	7	7	mild	mild	ADJ
dhrp-31	7	8	-	-	PUNCT
dhrp-31	7	9	moderate	moderate	ADJ
dhrp-31	7	10	sars	sar	NOUN
dhrp-31	7	11	-	-	PUNCT
dhrp-31	7	12	cov-2	cov-2	NOUN
dhrp-31	7	13	infection	infection	NOUN
dhrp-31	7	14	as	as	ADV
dhrp-31	7	15	well	well	ADV
dhrp-31	7	16	for	for	ADP
dhrp-31	7	17	post	post	ADJ
dhrp-31	7	18	-	-	ADJ
dhrp-31	7	19	exposure	exposure	ADJ
dhrp-31	7	20	prophylaxis	prophylaxis	NOUN
dhrp-31	7	21	in	in	ADP
dhrp-31	7	22	covid-19	covid-19	PROPN
dhrp-31	7	23	negative	negative	ADJ
dhrp-31	7	24	subjects	subject	NOUN
dhrp-31	7	25	.	.	PUNCT
dhrp-31	8	1	while	while	SCONJ
dhrp-31	8	2	effective	effective	ADJ
dhrp-31	8	3	,	,	PUNCT
dhrp-31	8	4	monoclonal	monoclonal	NOUN
dhrp-31	8	5	antibodies	antibody	NOUN
dhrp-31	8	6	have	have	VERB
dhrp-31	8	7	inherent	inherent	ADJ
dhrp-31	8	8	advantages	advantage	NOUN
dhrp-31	8	9	and	and	CCONJ
dhrp-31	8	10	disadvantages	disadvantage	NOUN
dhrp-31	8	11	when	when	SCONJ
dhrp-31	8	12	used	use	VERB
dhrp-31	8	13	for	for	ADP
dhrp-31	8	14	therapeutic	therapeutic	ADJ
dhrp-31	8	15	purposes	purpose	NOUN
dhrp-31	8	16	.	.	PUNCT
dhrp-31	9	1	produced	produce	VERB
dhrp-31	9	2	in	in	ADP
dhrp-31	9	3	vitro	vitro	X
dhrp-31	9	4	from	from	ADP
dhrp-31	9	5	immortalized	immortalized	ADJ
dhrp-31	9	6	plasma	plasma	NOUN
dhrp-31	9	7	cells	cell	NOUN
dhrp-31	9	8	,	,	PUNCT
dhrp-31	9	9	monoclonal	monoclonal	NOUN
dhrp-31	9	10	antibodies	antibody	NOUN
dhrp-31	9	11	have	have	VERB
dhrp-31	9	12	single	single	ADJ
dhrp-31	9	13	specificity	specificity	NOUN
dhrp-31	9	14	and	and	CCONJ
dhrp-31	9	15	affinity	affinity	NOUN
dhrp-31	9	16	which	which	PRON
dhrp-31	9	17	,	,	PUNCT
dhrp-31	9	18	reduces	reduce	VERB
dhrp-31	9	19	the	the	DET
dhrp-31	9	20	probability	probability	NOUN
dhrp-31	9	21	of	of	ADP
dhrp-31	9	22	cross	cross	NOUN
dhrp-31	9	23	reactivity	reactivity	NOUN
dhrp-31	9	24	(	(	PUNCT
dhrp-31	9	25	figure	figure	NOUN
dhrp-31	9	26	1	1	NUM
dhrp-31	9	27	)	)	PUNCT
dhrp-31	9	28	.	.	PUNCT
dhrp-31	10	1	due	due	ADP
dhrp-31	10	2	to	to	ADP
dhrp-31	10	3	batch	batch	VERB
dhrp-31	10	4	-	-	PUNCT
dhrp-31	10	5	to	to	ADP
dhrp-31	10	6	-	-	PUNCT
dhrp-31	10	7	batch	batch	NOUN
dhrp-31	10	8	homogeneity	homogeneity	NOUN
dhrp-31	10	9	,	,	PUNCT
dhrp-31	10	10	effectiveness	effectiveness	NOUN
dhrp-31	10	11	of	of	ADP
dhrp-31	10	12	monoclonal	monoclonal	NOUN
dhrp-31	10	13	antibodies	antibody	NOUN
dhrp-31	10	14	is	be	AUX
dhrp-31	10	15	much	much	ADV
dhrp-31	10	16	more	more	ADV
dhrp-31	10	17	predictable	predictable	ADJ
dhrp-31	10	18	,	,	PUNCT
dhrp-31	10	19	and	and	CCONJ
dhrp-31	10	20	they	they	PRON
dhrp-31	10	21	serve	serve	VERB
dhrp-31	10	22	as	as	ADP
dhrp-31	10	23	an	an	DET
dhrp-31	10	24	ideal	ideal	ADJ
dhrp-31	10	25	candidate	candidate	NOUN
dhrp-31	10	26	for	for	ADP
dhrp-31	10	27	use	use	NOUN
dhrp-31	10	28	in	in	ADP
dhrp-31	10	29	diagnostic	diagnostic	ADJ
dhrp-31	10	30	immunoassays	immunoassay	NOUN
dhrp-31	10	31	.	.	PUNCT
dhrp-31	11	1	a	a	DET
dhrp-31	11	2	distinct	distinct	ADJ
dhrp-31	11	3	disadvantage	disadvantage	NOUN
dhrp-31	11	4	of	of	ADP
dhrp-31	11	5	monoclonal	monoclonal	NOUN
dhrp-31	11	6	antibodies	antibody	NOUN
dhrp-31	11	7	is	be	AUX
dhrp-31	11	8	the	the	DET
dhrp-31	11	9	fact	fact	NOUN
dhrp-31	11	10	that	that	SCONJ
dhrp-31	11	11	due	due	ADP
dhrp-31	11	12	to	to	ADP
dhrp-31	11	13	its	its	PRON
dhrp-31	11	14	high	high	ADJ
dhrp-31	11	15	specificity	specificity	NOUN
dhrp-31	11	16	and	and	CCONJ
dhrp-31	11	17	affinity	affinity	NOUN
dhrp-31	11	18	,	,	PUNCT
dhrp-31	11	19	a	a	DET
dhrp-31	11	20	minor	minor	ADJ
dhrp-31	11	21	mutation	mutation	NOUN
dhrp-31	11	22	in	in	ADP
dhrp-31	11	23	the	the	DET
dhrp-31	11	24	epitope	epitope	NOUN
dhrp-31	11	25	often	often	ADV
dhrp-31	11	26	renders	render	VERB
dhrp-31	11	27	the	the	DET
dhrp-31	11	28	antibody	antibody	NOUN
dhrp-31	11	29	ineffective	ineffective	ADJ
dhrp-31	11	30	in	in	ADP
dhrp-31	11	31	neutralizing	neutralize	VERB
dhrp-31	11	32	the	the	DET
dhrp-31	11	33	target	target	NOUN
dhrp-31	11	34	.	.	PUNCT
dhrp-31	12	1	this	this	PRON
dhrp-31	12	2	is	be	AUX
dhrp-31	12	3	a	a	DET
dhrp-31	12	4	serious	serious	ADJ
dhrp-31	12	5	limitation	limitation	NOUN
dhrp-31	12	6	since	since	SCONJ
dhrp-31	12	7	observed	observe	VERB
dhrp-31	12	8	mutations	mutation	NOUN
dhrp-31	12	9	in	in	ADP
dhrp-31	12	10	sars	sar	NOUN
dhrp-31	12	11	-	-	PUNCT
dhrp-31	12	12	cov-2	cov-2	NOUN
dhrp-31	12	13	with	with	ADP
dhrp-31	12	14	generations	generation	NOUN
dhrp-31	12	15	of	of	ADP
dhrp-31	12	16	numerous	numerous	ADJ
dhrp-31	12	17	variants	variant	NOUN
dhrp-31	12	18	may	may	AUX
dhrp-31	12	19	render	render	VERB
dhrp-31	12	20	the	the	DET
dhrp-31	12	21	available	available	ADJ
dhrp-31	12	22	monoclonal	monoclonal	NOUN
dhrp-31	12	23	antibodies	antibodie	VERB
dhrp-31	12	24	less	less	ADV
dhrp-31	12	25	effective	effective	ADJ
dhrp-31	12	26	in	in	ADP
dhrp-31	12	27	mitigating	mitigate	VERB
dhrp-31	12	28	the	the	DET
dhrp-31	12	29	progression	progression	NOUN
dhrp-31	12	30	of	of	ADP
dhrp-31	12	31	covid-19	covid-19	PROPN
dhrp-31	12	32	.	.	PUNCT
dhrp-31	13	1	on	on	ADP
dhrp-31	13	2	the	the	DET
dhrp-31	13	3	contrary	contrary	NOUN
dhrp-31	13	4	,	,	PUNCT
dhrp-31	13	5	polyclonal	polyclonal	ADJ
dhrp-31	13	6	antibodies	antibody	NOUN
dhrp-31	13	7	are	be	AUX
dhrp-31	13	8	a	a	DET
dhrp-31	13	9	mixture	mixture	NOUN
dhrp-31	13	10	of	of	ADP
dhrp-31	13	11	monoclonal	monoclonal	NOUN
dhrp-31	13	12	antibodies	antibody	NOUN
dhrp-31	13	13	that	that	PRON
dhrp-31	13	14	are	be	AUX
dhrp-31	13	15	products	product	NOUN
dhrp-31	13	16	of	of	ADP
dhrp-31	13	17	multiple	multiple	ADJ
dhrp-31	13	18	b	b	PROPN
dhrp-31	13	19	cell	cell	NOUN
dhrp-31	13	20	clones	clone	NOUN
dhrp-31	13	21	.	.	PUNCT
dhrp-31	14	1	generated	generate	VERB
dhrp-31	14	2	in	in	ADP
dhrp-31	14	3	animals	animal	NOUN
dhrp-31	14	4	,	,	PUNCT
dhrp-31	14	5	polyclonal	polyclonal	ADJ
dhrp-31	14	6	antibodies	antibody	NOUN
dhrp-31	14	7	recognize	recognize	VERB
dhrp-31	14	8	with	with	ADP
dhrp-31	14	9	reasonably	reasonably	ADV
dhrp-31	14	10	high	high	ADJ
dhrp-31	14	11	affinity	affinity	NOUN
dhrp-31	14	12	multiple	multiple	NOUN
dhrp-31	14	13	epitopes	epitope	NOUN
dhrp-31	14	14	on	on	ADP
dhrp-31	14	15	a	a	DET
dhrp-31	14	16	single	single	ADJ
dhrp-31	14	17	antigen	antigen	NOUN
dhrp-31	14	18	(	(	PUNCT
dhrp-31	14	19	figure	figure	NOUN
dhrp-31	14	20	1	1	NUM
dhrp-31	14	21	)	)	PUNCT
dhrp-31	14	22	.	.	PUNCT
dhrp-31	15	1	this	this	DET
dhrp-31	15	2	affords	affords	ADJ
dhrp-31	15	3	polyclonal	polyclonal	NOUN
dhrp-31	15	4	antibodies	antibodie	VERB
dhrp-31	15	5	a	a	DET
dhrp-31	15	6	distinct	distinct	ADJ
dhrp-31	15	7	advantage	advantage	NOUN
dhrp-31	15	8	over	over	ADP
dhrp-31	15	9	monoclonal	monoclonal	NOUN
dhrp-31	15	10	antibodies	antibody	NOUN
dhrp-31	15	11	when	when	SCONJ
dhrp-31	15	12	used	use	VERB
dhrp-31	15	13	as	as	ADP
dhrp-31	15	14	therapeutic	therapeutic	ADJ
dhrp-31	15	15	agents	agent	NOUN
dhrp-31	15	16	particularly	particularly	ADV
dhrp-31	15	17	in	in	ADP
dhrp-31	15	18	patients	patient	NOUN
dhrp-31	15	19	infected	infect	VERB
dhrp-31	15	20	with	with	ADP
dhrp-31	15	21	rapidly	rapidly	ADV
dhrp-31	15	22	mutating	mutate	VERB
dhrp-31	15	23	sarscov-2	sarscov-2	NUM
dhrp-31	15	24	virus	virus	NOUN
dhrp-31	15	25	.	.	PUNCT
dhrp-31	16	1	figure	figure	VERB
dhrp-31	16	2	1	1	NUM
dhrp-31	16	3	:	:	PUNCT
dhrp-31	16	4	monoclonal	monoclonal	NOUN
dhrp-31	16	5	antibody	antibody	NOUN
dhrp-31	16	6	have	have	VERB
dhrp-31	16	7	affinity	affinity	NOUN
dhrp-31	16	8	for	for	ADP
dhrp-31	16	9	a	a	DET
dhrp-31	16	10	single	single	ADJ
dhrp-31	16	11	epitope	epitope	NOUN
dhrp-31	16	12	on	on	ADP
dhrp-31	16	13	the	the	DET
dhrp-31	16	14	antigen	antigen	NOUN
dhrp-31	16	15	(	(	PUNCT
dhrp-31	16	16	i.e.	i.e.	X
dhrp-31	16	17	,	,	PUNCT
dhrp-31	16	18	the	the	DET
dhrp-31	16	19	virus	virus	NOUN
dhrp-31	16	20	or	or	CCONJ
dhrp-31	16	21	the	the	DET
dhrp-31	16	22	bacteria	bacteria	NOUN
dhrp-31	16	23	)	)	PUNCT
dhrp-31	16	24	.	.	PUNCT
dhrp-31	17	1	on	on	ADP
dhrp-31	17	2	the	the	DET
dhrp-31	17	3	contrary	contrary	NOUN
dhrp-31	17	4	,	,	PUNCT
dhrp-31	17	5	polyclonal	polyclonal	ADJ
dhrp-31	17	6	antibodies	antibody	NOUN
dhrp-31	17	7	are	be	AUX
dhrp-31	17	8	a	a	DET
dhrp-31	17	9	mixture	mixture	NOUN
dhrp-31	17	10	of	of	ADP
dhrp-31	17	11	monoclonal	monoclonal	NOUN
dhrp-31	17	12	antibodies	antibody	NOUN
dhrp-31	17	13	with	with	ADP
dhrp-31	17	14	affinity	affinity	NOUN
dhrp-31	17	15	for	for	ADP
dhrp-31	17	16	various	various	ADJ
dhrp-31	17	17	epitopes	epitope	NOUN
dhrp-31	17	18	on	on	ADP
dhrp-31	17	19	the	the	DET
dhrp-31	17	20	antigen	antigen	NOUN
dhrp-31	17	21	.	.	PUNCT
dhrp-31	18	1	dhrp	dhrp	ADJ
dhrp-31	18	2	,	,	PUNCT
dhrp-31	18	3	2021	2021	NUM
dhrp-31	18	4	,	,	PUNCT
dhrp-31	18	5	vol	vol	NOUN
dhrp-31	18	6	.	.	NOUN
dhrp-31	18	7	1	1	NUM
dhrp-31	18	8	(	(	PUNCT
dhrp-31	18	9	s5	s5	NOUN
dhrp-31	18	10	)	)	PUNCT
dhrp-31	18	11	1	1	NUM
dhrp-31	18	12	-	-	SYM
dhrp-31	18	13	3	3	NUM
dhrp-31	18	14	editorial	editorial	NOUN
dhrp-31	18	15	http://dhrproceedings.org	http://dhrproceedings.org	PROPN
dhrp-31	18	16	2	2	NUM
dhrp-31	18	17	©	©	PROPN
dhrp-31	18	18	dhr	dhr	PROPN
dhrp-31	18	19	health	health	PROPN
dhrp-31	18	20	institute	institute	PROPN
dhrp-31	18	21	for	for	ADP
dhrp-31	18	22	research	research	NOUN
dhrp-31	18	23	and	and	CCONJ
dhrp-31	18	24	development	development	NOUN
dhrp-31	18	25	on	on	ADP
dhrp-31	18	26	april	april	PROPN
dhrp-31	18	27	17	17	NUM
dhrp-31	18	28	,	,	PUNCT
dhrp-31	18	29	2020	2020	NUM
dhrp-31	18	30	,	,	PUNCT
dhrp-31	18	31	the	the	DET
dhrp-31	18	32	national	national	PROPN
dhrp-31	18	33	institutes	institutes	PROPN
dhrp-31	18	34	of	of	ADP
dhrp-31	18	35	health	health	PROPN
dhrp-31	18	36	(	(	PUNCT
dhrp-31	18	37	nih	nih	PROPN
dhrp-31	18	38	)	)	PUNCT
dhrp-31	18	39	announced	announce	VERB
dhrp-31	18	40	the	the	DET
dhrp-31	18	41	accelerating	accelerate	VERB
dhrp-31	18	42	covid-19	covid-19	PROPN
dhrp-31	18	43	therapeutic	therapeutic	ADJ
dhrp-31	18	44	interventions	intervention	NOUN
dhrp-31	18	45	and	and	CCONJ
dhrp-31	18	46	vaccines	vaccine	NOUN
dhrp-31	18	47	(	(	PUNCT
dhrp-31	18	48	activ	activ	ADJ
dhrp-31	18	49	)	)	PUNCT
dhrp-31	18	50	public	public	ADJ
dhrp-31	18	51	-	-	PUNCT
dhrp-31	18	52	private	private	ADJ
dhrp-31	18	53	partnership	partnership	NOUN
dhrp-31	18	54	to	to	PART
dhrp-31	18	55	develop	develop	VERB
dhrp-31	18	56	a	a	DET
dhrp-31	18	57	coordinated	coordinated	ADJ
dhrp-31	18	58	research	research	NOUN
dhrp-31	18	59	strategy	strategy	NOUN
dhrp-31	18	60	for	for	ADP
dhrp-31	18	61	prioritizing	prioritize	VERB
dhrp-31	18	62	and	and	CCONJ
dhrp-31	18	63	speeding	speed	VERB
dhrp-31	18	64	development	development	NOUN
dhrp-31	18	65	of	of	ADP
dhrp-31	18	66	the	the	DET
dhrp-31	18	67	most	most	ADV
dhrp-31	18	68	promising	promising	ADJ
dhrp-31	18	69	treatments	treatment	NOUN
dhrp-31	18	70	and	and	CCONJ
dhrp-31	18	71	vaccines	vaccine	NOUN
dhrp-31	18	72	.	.	PUNCT
dhrp-31	19	1	activ	activ	PROPN
dhrp-31	19	2	was	be	AUX
dhrp-31	19	3	based	base	VERB
dhrp-31	19	4	on	on	ADP
dhrp-31	19	5	bayesian	bayesian	NOUN
dhrp-31	19	6	adaptive	adaptive	ADJ
dhrp-31	19	7	clinical	clinical	ADJ
dhrp-31	19	8	trial	trial	NOUN
dhrp-31	19	9	design	design	NOUN
dhrp-31	19	10	which	which	PRON
dhrp-31	19	11	allows	allow	VERB
dhrp-31	19	12	for	for	ADP
dhrp-31	19	13	frequent	frequent	ADJ
dhrp-31	19	14	“	"	PUNCT
dhrp-31	19	15	looks	look	NOUN
dhrp-31	19	16	”	"	PUNCT
dhrp-31	19	17	at	at	ADP
dhrp-31	19	18	the	the	DET
dhrp-31	19	19	data	datum	NOUN
dhrp-31	19	20	and	and	CCONJ
dhrp-31	19	21	permits	permit	VERB
dhrp-31	19	22	data	data	NOUN
dhrp-31	19	23	-	-	PUNCT
dhrp-31	19	24	driven	drive	VERB
dhrp-31	19	25	modifications	modification	NOUN
dhrp-31	19	26	during	during	ADP
dhrp-31	19	27	the	the	DET
dhrp-31	19	28	course	course	NOUN
dhrp-31	19	29	of	of	ADP
dhrp-31	19	30	the	the	DET
dhrp-31	19	31	study	study	NOUN
dhrp-31	19	32	(	(	PUNCT
dhrp-31	19	33	5	5	NUM
dhrp-31	19	34	)	)	PUNCT
dhrp-31	19	35	.	.	PUNCT
dhrp-31	20	1	dhr	dhr	PROPN
dhrp-31	20	2	health	health	PROPN
dhrp-31	20	3	institute	institute	PROPN
dhrp-31	20	4	for	for	ADP
dhrp-31	20	5	research	research	NOUN
dhrp-31	20	6	and	and	CCONJ
dhrp-31	20	7	development	development	NOUN
dhrp-31	20	8	is	be	AUX
dhrp-31	20	9	part	part	NOUN
dhrp-31	20	10	of	of	ADP
dhrp-31	20	11	the	the	DET
dhrp-31	20	12	activ	activ	PROPN
dhrp-31	20	13	collaborative	collaborative	NOUN
dhrp-31	20	14	and	and	CCONJ
dhrp-31	20	15	have	have	AUX
dhrp-31	20	16	initiated	initiate	VERB
dhrp-31	20	17	numerous	numerous	ADJ
dhrp-31	20	18	studies	study	NOUN
dhrp-31	20	19	in	in	ADP
dhrp-31	20	20	an	an	DET
dhrp-31	20	21	attempt	attempt	NOUN
dhrp-31	20	22	to	to	PART
dhrp-31	20	23	find	find	VERB
dhrp-31	20	24	the	the	DET
dhrp-31	20	25	most	most	ADV
dhrp-31	20	26	promising	promising	ADJ
dhrp-31	20	27	therapeutic	therapeutic	ADJ
dhrp-31	20	28	agent	agent	NOUN
dhrp-31	20	29	to	to	PART
dhrp-31	20	30	prevent	prevent	VERB
dhrp-31	20	31	and/or	and/or	CCONJ
dhrp-31	20	32	treat	treat	VERB
dhrp-31	20	33	patients	patient	NOUN
dhrp-31	20	34	with	with	ADP
dhrp-31	20	35	covid-19	covid-19	PROPN
dhrp-31	20	36	.	.	PUNCT
dhrp-31	21	1	as	as	ADP
dhrp-31	21	2	part	part	NOUN
dhrp-31	21	3	of	of	ADP
dhrp-31	21	4	activ-2	activ-2	PROPN
dhrp-31	21	5	,	,	PUNCT
dhrp-31	21	6	dhr	dhr	PROPN
dhrp-31	21	7	health	health	PROPN
dhrp-31	21	8	institute	institute	PROPN
dhrp-31	21	9	for	for	ADP
dhrp-31	21	10	research	research	PROPN
dhrp-31	21	11	&	&	CCONJ
dhrp-31	21	12	development	development	NOUN
dhrp-31	21	13	has	have	AUX
dhrp-31	21	14	initiated	initiate	VERB
dhrp-31	21	15	a	a	DET
dhrp-31	21	16	prospective	prospective	ADJ
dhrp-31	21	17	phase	phase	NOUN
dhrp-31	21	18	2/3	2/3	NUM
dhrp-31	21	19	clinical	clinical	ADJ
dhrp-31	21	20	trial	trial	NOUN
dhrp-31	21	21	to	to	PART
dhrp-31	21	22	evaluate	evaluate	VERB
dhrp-31	21	23	the	the	DET
dhrp-31	21	24	efficacy	efficacy	NOUN
dhrp-31	21	25	of	of	ADP
dhrp-31	21	26	fully	fully	ADV
dhrp-31	21	27	human	human	ADJ
dhrp-31	21	28	anti	anti	ADJ
dhrp-31	21	29	-	-	ADJ
dhrp-31	21	30	sars	sars	ADJ
dhrp-31	21	31	-	-	PUNCT
dhrp-31	21	32	cov-2	cov-2	NOUN
dhrp-31	21	33	polyclonal	polyclonal	ADJ
dhrp-31	21	34	antibody	antibody	NOUN
dhrp-31	21	35	(	(	PUNCT
dhrp-31	21	36	sab-185	sab-185	INTJ
dhrp-31	21	37	;	;	PUNCT
dhrp-31	21	38	sab	sab	PROPN
dhrp-31	21	39	pharmaceuticals	pharmaceuticals	PROPN
dhrp-31	21	40	,	,	PUNCT
dhrp-31	21	41	inc	inc	PROPN
dhrp-31	21	42	.	.	PROPN
dhrp-31	21	43	)	)	PUNCT
dhrp-31	21	44	to	to	PART
dhrp-31	21	45	treat	treat	VERB
dhrp-31	21	46	unvaccinated	unvaccinate	VERB
dhrp-31	21	47	nonhospitalized	nonhospitalize	VERB
dhrp-31	21	48	high	high	ADJ
dhrp-31	21	49	-	-	PUNCT
dhrp-31	21	50	risk	risk	NOUN
dhrp-31	21	51	patients	patient	NOUN
dhrp-31	21	52	with	with	ADP
dhrp-31	21	53	mild	mild	ADJ
dhrp-31	21	54	-	-	PUNCT
dhrp-31	21	55	moderate	moderate	ADJ
dhrp-31	21	56	covid-19	covid-19	PROPN
dhrp-31	21	57	.	.	PUNCT
dhrp-31	22	1	sab-185	sab-185	PROPN
dhrp-31	22	2	is	be	AUX
dhrp-31	22	3	a	a	DET
dhrp-31	22	4	fully	fully	ADV
dhrp-31	22	5	human	human	ADJ
dhrp-31	22	6	,	,	PUNCT
dhrp-31	22	7	anti	anti	ADJ
dhrp-31	22	8	-	-	ADJ
dhrp-31	22	9	sarscov-2	sarscov-2	NUM
dhrp-31	22	10	immunoglobulin	immunoglobulin	NOUN
dhrp-31	22	11	produced	produce	VERB
dhrp-31	22	12	in	in	ADP
dhrp-31	22	13	transchromosomic	transchromosomic	ADJ
dhrp-31	22	14	bovines	bovine	NOUN
dhrp-31	22	15	(	(	PUNCT
dhrp-31	22	16	tc	tc	NOUN
dhrp-31	22	17	-	-	PUNCT
dhrp-31	22	18	higg	higg	NOUN
dhrp-31	22	19	-	-	PUNCT
dhrp-31	22	20	sars	sar	NOUN
dhrp-31	22	21	-	-	PUNCT
dhrp-31	22	22	cov2	cov2	PROPN
dhrp-31	22	23	)	)	PUNCT
dhrp-31	22	24	hyperimmunized	hyperimmunize	VERB
dhrp-31	22	25	with	with	ADP
dhrp-31	22	26	two	two	NUM
dhrp-31	22	27	doses	dose	NOUN
dhrp-31	22	28	of	of	ADP
dhrp-31	22	29	plasmid	plasmid	ADJ
dhrp-31	22	30	dna	dna	PROPN
dhrp-31	22	31	encoding	encode	VERB
dhrp-31	22	32	the	the	DET
dhrp-31	22	33	sars	sar	NOUN
dhrp-31	22	34	-	-	PUNCT
dhrp-31	22	35	cov-2	cov-2	NOUN
dhrp-31	22	36	wuhan	wuhan	PROPN
dhrp-31	22	37	strain	strain	PROPN
dhrp-31	22	38	s	s	PART
dhrp-31	22	39	gene	gene	NOUN
dhrp-31	22	40	,	,	PUNCT
dhrp-31	22	41	followed	follow	VERB
dhrp-31	22	42	by	by	ADP
dhrp-31	22	43	repeated	repeat	VERB
dhrp-31	22	44	immunization	immunization	NOUN
dhrp-31	22	45	with	with	ADP
dhrp-31	22	46	s	s	PRON
dhrp-31	22	47	protein	protein	NOUN
dhrp-31	22	48	purified	purify	VERB
dhrp-31	22	49	from	from	ADP
dhrp-31	22	50	insect	insect	NOUN
dhrp-31	22	51	cells	cell	NOUN
dhrp-31	22	52	(	(	PUNCT
dhrp-31	22	53	6,7	6,7	NUM
dhrp-31	22	54	)	)	PUNCT
dhrp-31	22	55	.	.	PUNCT
dhrp-31	23	1	the	the	DET
dhrp-31	23	2	resulting	result	VERB
dhrp-31	23	3	tc	tc	NUM
dhrp-31	23	4	-	-	PUNCT
dhrp-31	23	5	higg	higg	NOUN
dhrp-31	23	6	-	-	PUNCT
dhrp-31	23	7	sars	sar	NOUN
dhrp-31	23	8	-	-	PUNCT
dhrp-31	23	9	cov-2	cov-2	NOUN
dhrp-31	23	10	,	,	PUNCT
dhrp-31	23	11	termed	term	VERB
dhrp-31	23	12	sab-185	sab-185	PROPN
dhrp-31	23	13	,	,	PUNCT
dhrp-31	23	14	efficiently	efficiently	ADV
dhrp-31	23	15	neutralizes	neutralize	VERB
dhrp-31	23	16	sars	sar	NOUN
dhrp-31	23	17	-	-	PUNCT
dhrp-31	23	18	cov-2	cov-2	NOUN
dhrp-31	23	19	,	,	PUNCT
dhrp-31	23	20	and	and	CCONJ
dhrp-31	23	21	vesicular	vesicular	ADJ
dhrp-31	23	22	stomatitis	stomatitis	PROPN
dhrp-31	23	23	virus	virus	NOUN
dhrp-31	23	24	(	(	PUNCT
dhrp-31	23	25	vsv	vsv	PROPN
dhrp-31	23	26	)	)	PUNCT
dhrp-31	23	27	sars	sar	NOUN
dhrp-31	23	28	-	-	PUNCT
dhrp-31	23	29	cov-2	cov-2	NOUN
dhrp-31	23	30	chimeras	chimera	NOUN
dhrp-31	23	31	in	in	ADP
dhrp-31	23	32	vitro	vitro	VERB
dhrp-31	23	33	.	.	PUNCT
dhrp-31	24	1	this	this	DET
dhrp-31	24	2	fully	fully	ADV
dhrp-31	24	3	human	human	ADJ
dhrp-31	24	4	polyclonal	polyclonal	ADJ
dhrp-31	24	5	antibody	antibody	NOUN
dhrp-31	24	6	that	that	PRON
dhrp-31	24	7	potently	potently	ADV
dhrp-31	24	8	inhibits	inhibit	VERB
dhrp-31	24	9	sars	sar	NOUN
dhrp-31	24	10	-	-	PUNCT
dhrp-31	24	11	cov-2	cov-2	PART
dhrp-31	24	12	infection	infection	NOUN
dhrp-31	24	13	may	may	AUX
dhrp-31	24	14	provide	provide	VERB
dhrp-31	24	15	an	an	DET
dhrp-31	24	16	effective	effective	ADJ
dhrp-31	24	17	therapeutic	therapeutic	ADJ
dhrp-31	24	18	agent	agent	NOUN
dhrp-31	24	19	to	to	PART
dhrp-31	24	20	combat	combat	VERB
dhrp-31	24	21	covid-19	covid-19	PROPN
dhrp-31	24	22	.	.	PUNCT
dhrp-31	25	1	this	this	PRON
dhrp-31	25	2	is	be	AUX
dhrp-31	25	3	not	not	PART
dhrp-31	25	4	a	a	DET
dhrp-31	25	5	placebo	placebo	NOUN
dhrp-31	25	6	-	-	PUNCT
dhrp-31	25	7	controlled	control	VERB
dhrp-31	25	8	study	study	NOUN
dhrp-31	25	9	as	as	SCONJ
dhrp-31	25	10	the	the	DET
dhrp-31	25	11	patients	patient	NOUN
dhrp-31	25	12	in	in	ADP
dhrp-31	25	13	the	the	DET
dhrp-31	25	14	comparator	comparator	NOUN
dhrp-31	25	15	arm	arm	NOUN
dhrp-31	25	16	will	will	AUX
dhrp-31	25	17	be	be	AUX
dhrp-31	25	18	treated	treat	VERB
dhrp-31	25	19	with	with	ADP
dhrp-31	25	20	regen	regen	NOUN
dhrp-31	25	21	-	-	PUNCT
dhrp-31	25	22	cov	cov	NOUN
dhrp-31	25	23	monoclonal	monoclonal	NOUN
dhrp-31	25	24	antibody	antibody	NOUN
dhrp-31	25	25	.	.	PUNCT
dhrp-31	26	1	in	in	ADP
dhrp-31	26	2	conclusion	conclusion	NOUN
dhrp-31	26	3	,	,	PUNCT
dhrp-31	26	4	the	the	DET
dhrp-31	26	5	use	use	NOUN
dhrp-31	26	6	of	of	ADP
dhrp-31	26	7	available	available	ADJ
dhrp-31	26	8	anti	anti	ADJ
dhrp-31	26	9	-	-	ADJ
dhrp-31	26	10	sars	sars	ADJ
dhrp-31	26	11	-	-	PUNCT
dhrp-31	26	12	cov2	cov2	PROPN
dhrp-31	26	13	monoclonal	monoclonal	NOUN
dhrp-31	26	14	antibodies	antibody	NOUN
dhrp-31	26	15	has	have	AUX
dhrp-31	26	16	been	be	AUX
dhrp-31	26	17	effective	effective	ADJ
dhrp-31	26	18	in	in	ADP
dhrp-31	26	19	mitigating	mitigate	VERB
dhrp-31	26	20	the	the	DET
dhrp-31	26	21	progression	progression	NOUN
dhrp-31	26	22	of	of	ADP
dhrp-31	26	23	disease	disease	NOUN
dhrp-31	26	24	in	in	ADP
dhrp-31	26	25	high	high	ADJ
dhrp-31	26	26	-	-	PUNCT
dhrp-31	26	27	risk	risk	NOUN
dhrp-31	26	28	patients	patient	NOUN
dhrp-31	26	29	with	with	ADP
dhrp-31	26	30	mild	mild	ADJ
dhrp-31	26	31	-	-	PUNCT
dhrp-31	26	32	moderate	moderate	ADJ
dhrp-31	26	33	covid-19	covid-19	PROPN
dhrp-31	26	34	.	.	PUNCT
dhrp-31	27	1	however	however	ADV
dhrp-31	27	2	,	,	PUNCT
dhrp-31	27	3	it	it	PRON
dhrp-31	27	4	could	could	AUX
dhrp-31	27	5	be	be	AUX
dhrp-31	27	6	argued	argue	VERB
dhrp-31	27	7	that	that	SCONJ
dhrp-31	27	8	the	the	DET
dhrp-31	27	9	use	use	NOUN
dhrp-31	27	10	of	of	ADP
dhrp-31	27	11	fully	fully	ADV
dhrp-31	27	12	human	human	ADJ
dhrp-31	27	13	polyclonal	polyclonal	ADJ
dhrp-31	27	14	antibodies	antibodie	VERB
dhrp-31	27	15	with	with	ADP
dhrp-31	27	16	affinity	affinity	NOUN
dhrp-31	27	17	for	for	ADP
dhrp-31	27	18	multiple	multiple	ADJ
dhrp-31	27	19	epitopes	epitope	NOUN
dhrp-31	27	20	on	on	ADP
dhrp-31	27	21	sars	sar	NOUN
dhrp-31	27	22	-	-	PUNCT
dhrp-31	27	23	cov-2	cov-2	NUM
dhrp-31	27	24	may	may	AUX
dhrp-31	27	25	be	be	AUX
dhrp-31	27	26	more	more	ADV
dhrp-31	27	27	effective	effective	ADJ
dhrp-31	27	28	in	in	ADP
dhrp-31	27	29	eliminating	eliminate	VERB
dhrp-31	27	30	the	the	DET
dhrp-31	27	31	virus	virus	NOUN
dhrp-31	27	32	and	and	CCONJ
dhrp-31	27	33	its	its	PRON
dhrp-31	27	34	variants	variant	NOUN
dhrp-31	27	35	which	which	PRON
dhrp-31	27	36	exhibit	exhibit	VERB
dhrp-31	27	37	higher	high	ADJ
dhrp-31	27	38	transmissibility	transmissibility	NOUN
dhrp-31	27	39	,	,	PUNCT
dhrp-31	27	40	infectivity	infectivity	NOUN
dhrp-31	27	41	,	,	PUNCT
dhrp-31	27	42	and	and	CCONJ
dhrp-31	27	43	the	the	DET
dhrp-31	27	44	potential	potential	NOUN
dhrp-31	27	45	to	to	PART
dhrp-31	27	46	“	"	PUNCT
dhrp-31	27	47	escape	escape	VERB
dhrp-31	27	48	”	"	PUNCT
dhrp-31	27	49	from	from	ADP
dhrp-31	27	50	the	the	DET
dhrp-31	27	51	neutralizing	neutralizing	ADJ
dhrp-31	27	52	effects	effect	NOUN
dhrp-31	27	53	of	of	ADP
dhrp-31	27	54	existing	exist	VERB
dhrp-31	27	55	experimental	experimental	ADJ
dhrp-31	27	56	agents	agent	NOUN
dhrp-31	27	57	.	.	PUNCT
dhrp-31	28	1	references	reference	NOUN
dhrp-31	28	2	1	1	NUM
dhrp-31	28	3	.	.	PUNCT
dhrp-31	29	1	emergency	emergency	NOUN
dhrp-31	29	2	use	use	NOUN
dhrp-31	29	3	authorization	authorization	NOUN
dhrp-31	29	4	(	(	PUNCT
dhrp-31	29	5	eua	eua	PROPN
dhrp-31	29	6	)	)	PUNCT
dhrp-31	29	7	for	for	ADP
dhrp-31	29	8	bamlanivimab	bamlanivimab	NOUN
dhrp-31	29	9	700	700	NUM
dhrp-31	29	10	mg	mg	NUM
dhrp-31	29	11	iv	iv	NOUN
dhrp-31	29	12	center	center	NOUN
dhrp-31	29	13	for	for	ADP
dhrp-31	29	14	drug	drug	NOUN
dhrp-31	29	15	evaluation	evaluation	NOUN
dhrp-31	29	16	and	and	CCONJ
dhrp-31	29	17	research	research	NOUN
dhrp-31	29	18	(	(	PUNCT
dhrp-31	29	19	cder	cder	NOUN
dhrp-31	29	20	)	)	PUNCT
dhrp-31	29	21	review	review	NOUN
dhrp-31	29	22	.	.	PUNCT
dhrp-31	30	1	2020	2020	NUM
dhrp-31	30	2	.	.	PUNCT
dhrp-31	30	3	https://www.fda.gov/media/144118/download	https://www.fda.gov/media/144118/download	PROPN
dhrp-31	30	4	(	(	PUNCT
dhrp-31	30	5	accessed	access	VERB
dhrp-31	30	6	october	october	PROPN
dhrp-31	30	7	26	26	NUM
dhrp-31	30	8	,	,	PUNCT
dhrp-31	30	9	2021	2021	NUM
dhrp-31	30	10	)	)	PUNCT
dhrp-31	30	11	.	.	PUNCT
dhrp-31	31	1	2	2	X
dhrp-31	31	2	.	.	X
dhrp-31	31	3	emergency	emergency	NOUN
dhrp-31	31	4	use	use	NOUN
dhrp-31	31	5	authorization	authorization	NOUN
dhrp-31	31	6	for	for	ADP
dhrp-31	31	7	regen	regen	NOUN
dhrp-31	31	8	-	-	PUNCT
dhrp-31	31	9	cov	cov	NOUN
dhrp-31	31	10	for	for	ADP
dhrp-31	31	11	the	the	DET
dhrp-31	31	12	treatment	treatment	NOUN
dhrp-31	31	13	of	of	ADP
dhrp-31	31	14	mild	mild	ADJ
dhrp-31	31	15	-	-	PUNCT
dhrp-31	31	16	moderate	moderate	ADJ
dhrp-31	31	17	covid-19	covid-19	PROPN
dhrp-31	31	18	.	.	PROPN
dhrp-31	31	19	2020	2020	NUM
dhrp-31	31	20	.	.	PUNCT
dhrp-31	32	1	https://www.fda.gov/media/145610/download	https://www.fda.gov/media/145610/download	X
dhrp-31	32	2	.	.	PUNCT
dhrp-31	33	1	(	(	PUNCT
dhrp-31	33	2	accessed	access	VERB
dhrp-31	33	3	october	october	PROPN
dhrp-31	33	4	26	26	NUM
dhrp-31	33	5	,	,	PUNCT
dhrp-31	33	6	2021	2021	NUM
dhrp-31	33	7	)	)	PUNCT
dhrp-31	33	8	.	.	PUNCT
dhrp-31	34	1	3	3	X
dhrp-31	34	2	.	.	X
dhrp-31	34	3	fda	fda	PROPN
dhrp-31	34	4	revokes	revoke	VERB
dhrp-31	34	5	initial	initial	ADJ
dhrp-31	34	6	emergency	emergency	NOUN
dhrp-31	34	7	use	use	NOUN
dhrp-31	34	8	authorization	authorization	NOUN
dhrp-31	34	9	of	of	ADP
dhrp-31	34	10	monotherapy	monotherapy	NOUN
dhrp-31	34	11	with	with	ADP
dhrp-31	34	12	bamlanivimab	bamlanivimab	NOUN
dhrp-31	34	13	.	.	PUNCT
dhrp-31	35	1	march	march	PROPN
dhrp-31	35	2	2021	2021	NUM
dhrp-31	35	3	.	.	PUNCT
dhrp-31	36	1	https://www.fda.gov/media/143602/download	https://www.fda.gov/media/143602/download	PRON
dhrp-31	36	2	(	(	PUNCT
dhrp-31	36	3	accessed	access	VERB
dhrp-31	36	4	october	october	PROPN
dhrp-31	36	5	27	27	NUM
dhrp-31	36	6	,	,	PUNCT
dhrp-31	36	7	2021	2021	NUM
dhrp-31	36	8	)	)	PUNCT
dhrp-31	36	9	.	.	PUNCT
dhrp-31	37	1	4	4	X
dhrp-31	37	2	.	.	X
dhrp-31	37	3	fda	fda	PROPN
dhrp-31	37	4	authorizes	authorize	VERB
dhrp-31	37	5	additional	additional	ADJ
dhrp-31	37	6	monoclonal	monoclonal	NOUN
dhrp-31	37	7	antibody	antibody	NOUN
dhrp-31	37	8	for	for	ADP
dhrp-31	37	9	treatment	treatment	NOUN
dhrp-31	37	10	of	of	ADP
dhrp-31	37	11	covid-19	covid-19	PROPN
dhrp-31	37	12	.	.	PROPN
dhrp-31	37	13	2021	2021	NUM
dhrp-31	37	14	.	.	PUNCT
dhrp-31	38	1	https://www.fda.gov/newsevents/press-announcements/coronavirus-covid-19-update-fdaauthorizes-additional-monoclonal-antibody-treatment-covid-19	https://www.fda.gov/newsevents/press-announcements/coronavirus-covid-19-update-fdaauthorizes-additional-monoclonal-antibody-treatment-covid-19	PROPN
dhrp-31	38	2	.	.	PUNCT
dhrp-31	39	1	(	(	PUNCT
dhrp-31	39	2	accessed	access	VERB
dhrp-31	39	3	october	october	PROPN
dhrp-31	39	4	27	27	NUM
dhrp-31	39	5	,	,	PUNCT
dhrp-31	39	6	2021	2021	NUM
dhrp-31	39	7	)	)	PUNCT
dhrp-31	39	8	.	.	PUNCT
dhrp-31	40	1	5	5	X
dhrp-31	40	2	.	.	X
dhrp-31	40	3	giovagnoli	giovagnoli	ADJ
dhrp-31	40	4	a.	a.	NOUN
dhrp-31	40	5	(	(	PUNCT
dhrp-31	40	6	2021	2021	NUM
dhrp-31	40	7	)	)	PUNCT
dhrp-31	40	8	.	.	PUNCT
dhrp-31	41	1	the	the	DET
dhrp-31	41	2	bayesian	bayesian	NOUN
dhrp-31	41	3	design	design	NOUN
dhrp-31	41	4	of	of	ADP
dhrp-31	41	5	adaptive	adaptive	ADJ
dhrp-31	41	6	clinical	clinical	ADJ
dhrp-31	41	7	trials	trial	NOUN
dhrp-31	41	8	.	.	PUNCT
dhrp-31	42	1	international	international	ADJ
dhrp-31	42	2	journal	journal	PROPN
dhrp-31	42	3	of	of	ADP
dhrp-31	42	4	environmental	environmental	ADJ
dhrp-31	42	5	research	research	NOUN
dhrp-31	42	6	and	and	CCONJ
dhrp-31	42	7	public	public	ADJ
dhrp-31	42	8	health	health	NOUN
dhrp-31	42	9	,	,	PUNCT
dhrp-31	42	10	18(2	18(2	NUM
dhrp-31	42	11	)	)	PUNCT
dhrp-31	42	12	,	,	PUNCT
dhrp-31	42	13	530	530	NUM
dhrp-31	42	14	.	.	PUNCT
dhrp-31	42	15	https://doi.org/10.3390/ijerph18020530	https://doi.org/10.3390/ijerph18020530	PROPN
dhrp-31	42	16	6	6	NUM
dhrp-31	42	17	.	.	PUNCT
dhrp-31	43	1	gilliland	gilliland	PROPN
dhrp-31	43	2	t	t	PROPN
dhrp-31	43	3	,	,	PUNCT
dhrp-31	43	4	liu	liu	PROPN
dhrp-31	43	5	y	y	PROPN
dhrp-31	43	6	,	,	PUNCT
dhrp-31	43	7	li	li	PROPN
dhrp-31	43	8	r	r	PROPN
dhrp-31	43	9	,	,	PUNCT
dhrp-31	43	10	dunn	dunn	PROPN
dhrp-31	43	11	m	m	PROPN
dhrp-31	43	12	,	,	PUNCT
dhrp-31	43	13	cottle	cottle	PROPN
dhrp-31	43	14	e	e	PROPN
dhrp-31	43	15	,	,	PUNCT
dhrp-31	43	16	terada	terada	PROPN
dhrp-31	43	17	y	y	PROPN
dhrp-31	43	18	,	,	PUNCT
dhrp-31	43	19	rickman	rickman	PROPN
dhrp-31	43	20	z	z	PROPN
dhrp-31	43	21	,	,	PUNCT
dhrp-31	43	22	alcorn	alcorn	PROPN
dhrp-31	43	23	m	m	PROPN
dhrp-31	43	24	,	,	PUNCT
dhrp-31	43	25	vasilatos	vasilatos	NOUN
dhrp-31	43	26	s	s	PART
dhrp-31	43	27	,	,	PUNCT
dhrp-31	43	28	lundy	lundy	PROPN
dhrp-31	43	29	j	j	PROPN
dhrp-31	43	30	,	,	PUNCT
dhrp-31	43	31	larson	larson	PROPN
dhrp-31	43	32	d	d	PROPN
dhrp-31	43	33	,	,	PUNCT
dhrp-31	43	34	wu	wu	PROPN
dhrp-31	43	35	h	h	PROPN
dhrp-31	43	36	,	,	PUNCT
dhrp-31	43	37	luke	luke	PROPN
dhrp-31	43	38	t	t	PROPN
dhrp-31	43	39	,	,	PUNCT
dhrp-31	43	40	bausch	bausch	PROPN
dhrp-31	43	41	c	c	PROPN
dhrp-31	43	42	,	,	PUNCT
dhrp-31	43	43	egland	egland	PROPN
dhrp-31	43	44	k	k	NOUN
dhrp-31	43	45	,	,	PUNCT
dhrp-31	43	46	sullivan	sullivan	PROPN
dhrp-31	43	47	e	e	PROPN
dhrp-31	43	48	,	,	PUNCT
dhrp-31	43	49	wang	wang	PROPN
dhrp-31	43	50	z	z	PROPN
dhrp-31	43	51	,	,	PUNCT
dhrp-31	44	1	klimstra	klimstra	PROPN
dhrp-31	44	2	wb	wb	PROPN
dhrp-31	44	3	.	.	PROPN
dhrp-31	44	4	protection	protection	NOUN
dhrp-31	44	5	of	of	ADP
dhrp-31	44	6	human	human	ADJ
dhrp-31	44	7	ace2	ace2	NOUN
dhrp-31	44	8	transgenic	transgenic	NOUN
dhrp-31	44	9	syrian	syrian	ADJ
dhrp-31	44	10	hamsters	hamster	NOUN
dhrp-31	44	11	from	from	ADP
dhrp-31	44	12	sars	sars	PROPN
dhrp-31	44	13	cov-2	cov-2	PART
dhrp-31	44	14	variants	variant	NOUN
dhrp-31	44	15	by	by	ADP
dhrp-31	44	16	human	human	ADJ
dhrp-31	44	17	polyclonal	polyclonal	ADJ
dhrp-31	44	18	igg	igg	PROPN
dhrp-31	44	19	from	from	ADP
dhrp-31	44	20	hyperimmunized	hyperimmunize	VERB
dhrp-31	44	21	transchromosomic	transchromosomic	ADJ
dhrp-31	44	22	bovines	bovine	NOUN
dhrp-31	44	23	.	.	PUNCT
dhrp-31	45	1	biorxiv	biorxiv	NOUN
dhrp-31	46	1	[	[	X
dhrp-31	46	2	preprint	preprint	NOUN
dhrp-31	46	3	]	]	X
dhrp-31	46	4	.	.	PUNCT
dhrp-31	47	1	2021	2021	NUM
dhrp-31	47	2	jul	jul	PROPN
dhrp-31	47	3	26:2021.07.26.453840	26:2021.07.26.453840	NUM
dhrp-31	47	4	.	.	PUNCT
dhrp-31	48	1	doi	doi	PROPN
dhrp-31	48	2	:	:	PUNCT
dhrp-31	48	3	10.1101/2021.07.26.453840	10.1101/2021.07.26.453840	NUM
dhrp-31	48	4	.	.	PUNCT
dhrp-31	49	1	pmid	pmid	NOUN
dhrp-31	49	2	:	:	PUNCT
dhrp-31	49	3	34341790	34341790	NUM
dhrp-31	49	4	;	;	PUNCT
dhrp-31	49	5	pmcid	pmcid	NOUN
dhrp-31	49	6	:	:	PUNCT
dhrp-31	49	7	pmc8328057	pmc8328057	ADJ
dhrp-31	49	8	.	.	PUNCT
dhrp-31	50	1	7	7	X
dhrp-31	50	2	.	.	X
dhrp-31	51	1	liu	liu	PROPN
dhrp-31	51	2	z	z	PROPN
dhrp-31	51	3	,	,	PUNCT
dhrp-31	51	4	wu	wu	PROPN
dhrp-31	51	5	h	h	PROPN
dhrp-31	51	6	,	,	PUNCT
dhrp-31	51	7	egland	egland	PROPN
dhrp-31	51	8	ka	ka	PROPN
dhrp-31	51	9	,	,	PUNCT
dhrp-31	51	10	gilliland	gilliland	PROPN
dhrp-31	51	11	tc	tc	PROPN
dhrp-31	51	12	,	,	PUNCT
dhrp-31	51	13	dunn	dunn	PROPN
dhrp-31	51	14	md	md	PROPN
dhrp-31	51	15	,	,	PUNCT
dhrp-31	51	16	luke	luke	PROPN
dhrp-31	51	17	tc	tc	PROPN
dhrp-31	51	18	,	,	PUNCT
dhrp-31	51	19	sullivan	sullivan	PROPN
dhrp-31	51	20	ej	ej	PROPN
dhrp-31	51	21	,	,	PUNCT
dhrp-31	51	22	klimstra	klimstra	PROPN
dhrp-31	51	23	wb	wb	PROPN
dhrp-31	51	24	,	,	PUNCT
dhrp-31	51	25	bausch	bausch	PROPN
dhrp-31	51	26	cl	cl	PROPN
dhrp-31	51	27	,	,	PUNCT
dhrp-31	51	28	whelan	whelan	PROPN
dhrp-31	51	29	spj	spj	PROPN
dhrp-31	51	30	.	.	PUNCT
dhrp-31	52	1	human	human	ADJ
dhrp-31	52	2	immunoglobulin	immunoglobulin	NOUN
dhrp-31	52	3	from	from	ADP
dhrp-31	52	4	transchromosomic	transchromosomic	ADJ
dhrp-31	52	5	bovines	bovine	NOUN
dhrp-31	52	6	hyperimmunized	hyperimmunize	VERB
dhrp-31	52	7	with	with	ADP
dhrp-31	52	8	sars	sar	NOUN
dhrp-31	52	9	-	-	PUNCT
dhrp-31	52	10	cov-2	cov-2	NOUN
dhrp-31	52	11	spike	spike	NOUN
dhrp-31	52	12	antigen	antigen	NOUN
dhrp-31	52	13	efficiently	efficiently	ADV
dhrp-31	52	14	neutralizes	neutralize	VERB
dhrp-31	52	15	viral	viral	ADJ
dhrp-31	52	16	variants	variant	NOUN
dhrp-31	52	17	.	.	PUNCT
dhrp-31	53	1	hum	hum	PROPN
dhrp-31	53	2	vaccin	vaccin	PROPN
dhrp-31	53	3	immunother	immunother	PROPN
dhrp-31	53	4	.	.	PUNCT
dhrp-31	54	1	2021	2021	NUM
dhrp-31	54	2	jul	jul	PROPN
dhrp-31	54	3	6:1	6:1	NUM
dhrp-31	54	4	-	-	SYM
dhrp-31	54	5	10	10	NUM
dhrp-31	54	6	.	.	PUNCT
dhrp-31	55	1	doi:10.1080/21645515.2021.1940652	doi:10.1080/21645515.2021.1940652	NOUN
dhrp-31	55	2	.	.	PUNCT
dhrp-31	55	3	epub	epub	PROPN
dhrp-31	55	4	ahead	ahead	ADV
dhrp-31	55	5	of	of	ADP
dhrp-31	55	6	print	print	NOUN
dhrp-31	55	7	.	.	PUNCT
dhrp-31	56	1	pmid	pmid	NOUN
dhrp-31	56	2	:	:	PUNCT
dhrp-31	56	3	34228597	34228597	NUM
dhrp-31	56	4	;	;	PUNCT
dhrp-31	56	5	pmcid	pmcid	NOUN
dhrp-31	56	6	:	:	PUNCT
dhrp-31	56	7	pmc8290372	pmc8290372	PROPN
dhrp-31	56	8	.	.	PUNCT
dhrp-31	57	1	sohail	sohail	PROPN
dhrp-31	57	2	rao	rao	PROPN
dhrp-31	57	3	,	,	PUNCT
dhrp-31	57	4	md	md	PROPN
dhrp-31	57	5	,	,	PUNCT
dhrp-31	57	6	ma	ma	PROPN
dhrp-31	57	7	,	,	PUNCT
dhrp-31	57	8	dphil	dphil	ADJ
dhrp-31	57	9	executive	executive	ADJ
dhrp-31	57	10	vice	vice	NOUN
dhrp-31	57	11	president	president	NOUN
dhrp-31	57	12	,	,	PUNCT
dhrp-31	57	13	dhr	dhr	PROPN
dhrp-31	57	14	health	health	PROPN
dhrp-31	57	15	,	,	PUNCT
dhrp-31	57	16	5501	5501	NUM
dhrp-31	57	17	s.	s.	PROPN
dhrp-31	57	18	mccoll	mccoll	PROPN
dhrp-31	57	19	road	road	PROPN
dhrp-31	57	20	,	,	PUNCT
dhrp-31	57	21	edinburg	edinburg	PROPN
dhrp-31	57	22	,	,	PUNCT
dhrp-31	57	23	texas	texas	PROPN
dhrp-31	57	24	president	president	PROPN
dhrp-31	57	25	&	&	CCONJ
dhrp-31	57	26	chief	chief	ADJ
dhrp-31	57	27	executive	executive	ADJ
dhrp-31	57	28	officer	officer	NOUN
dhrp-31	57	29	,	,	PUNCT
dhrp-31	57	30	dhr	dhr	PROPN
dhrp-31	57	31	health	health	PROPN
dhrp-31	57	32	institute	institute	PROPN
dhrp-31	57	33	for	for	ADP
dhrp-31	57	34	research	research	PROPN
dhrp-31	57	35	&	&	CCONJ
dhrp-31	57	36	development	development	PROPN
dhrp-31	57	37	,	,	PUNCT
dhrp-31	57	38	5323	5323	NUM
dhrp-31	57	39	s.	s.	PROPN
dhrp-31	57	40	mccoll	mccoll	PROPN
dhrp-31	57	41	road	road	PROPN
dhrp-31	57	42	,	,	PUNCT
dhrp-31	57	43	edinburg	edinburg	PROPN
dhrp-31	57	44	,	,	PUNCT
dhrp-31	57	45	texas	texas	PROPN
dhrp-31	57	46	corresponding	corresponding	PROPN
dhrp-31	57	47	author	author	NOUN
dhrp-31	57	48	email	email	NOUN
dhrp-31	57	49	:	:	PUNCT
dhrp-31	57	50	s.rao@dhr-rgv.com	s.rao@dhr-rgv.com	X
dhrp-31	57	51	disclosures	disclosure	NOUN
dhrp-31	57	52	:	:	PUNCT
dhrp-31	57	53	none	none	NOUN
dhrp-31	57	54	orcid	orcid	NOUN
dhrp-31	57	55	:	:	PUNCT
dhrp-31	57	56	sohail	sohail	PROPN
dhrp-31	57	57	rao	rao	PROPN
dhrp-31	57	58	:	:	PUNCT
dhrp-31	57	59	https://orcid.org/0000-0001-50279992	https://orcid.org/0000-0001-50279992	PROPN
dhrp-31	57	60	https://www.fda.gov/media/144118/download	https://www.fda.gov/media/144118/download	X
dhrp-31	57	61	https://www.fda.gov/media/145610/download	https://www.fda.gov/media/145610/download	ADJ
dhrp-31	57	62	https://www.fda.gov/media/143602/download	https://www.fda.gov/media/143602/download	ADV
dhrp-31	58	1	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19	INTJ
dhrp-31	59	1	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19	CCONJ
dhrp-31	60	1	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19	PRON
dhrp-31	60	2	https://doi.org/10.3390/ijerph18020530	https://doi.org/10.3390/ijerph18020530	PROPN
dhrp-31	60	3	https://orcid.org/0000-0001-5027-9992	https://orcid.org/0000-0001-5027-9992	PROPN
dhrp-31	60	4	https://orcid.org/0000-0001-5027-9992	https://orcid.org/0000-0001-5027-9992	PROPN
dhrp-31	60	5	dhrp	dhrp	ADJ
dhrp-31	60	6	,	,	PUNCT
dhrp-31	60	7	2021	2021	NUM
dhrp-31	60	8	,	,	PUNCT
dhrp-31	60	9	vol	vol	NOUN
dhrp-31	60	10	.	.	NOUN
dhrp-31	60	11	1	1	NUM
dhrp-31	60	12	(	(	PUNCT
dhrp-31	60	13	s5	s5	NOUN
dhrp-31	60	14	)	)	PUNCT
dhrp-31	60	15	1	1	NUM
dhrp-31	60	16	-	-	SYM
dhrp-31	60	17	3	3	NUM
dhrp-31	60	18	editorial	editorial	NOUN
dhrp-31	60	19	http://dhrproceedings.org	http://dhrproceedings.org	PROPN
dhrp-31	60	20	3	3	NUM
dhrp-31	60	21	©	©	PROPN
dhrp-31	60	22	dhr	dhr	PROPN
dhrp-31	60	23	health	health	PROPN
dhrp-31	60	24	institute	institute	PROPN
dhrp-31	60	25	for	for	ADP
dhrp-31	60	26	research	research	NOUN
dhrp-31	60	27	and	and	CCONJ
dhrp-31	60	28	development	development	PROPN
dhrp-31	60	29	caitlin	caitlin	PROPN
dhrp-31	60	30	white	white	PROPN
dhrp-31	60	31	dhr	dhr	PROPN
dhrp-31	60	32	health	health	PROPN
dhrp-31	60	33	institute	institute	PROPN
dhrp-31	60	34	for	for	ADP
dhrp-31	60	35	research	research	PROPN
dhrp-31	60	36	&	&	CCONJ
dhrp-31	60	37	development	development	PROPN
dhrp-31	60	38	,	,	PUNCT
dhrp-31	60	39	5323	5323	NUM
dhrp-31	60	40	s.	s.	PROPN
dhrp-31	60	41	mccoll	mccoll	PROPN
dhrp-31	60	42	road	road	PROPN
dhrp-31	60	43	,	,	PUNCT
dhrp-31	60	44	edinburg	edinburg	PROPN
dhrp-31	60	45	,	,	PUNCT
dhrp-31	60	46	tx	tx	PROPN
dhrp-31	60	47	78539	78539	NUM
dhrp-31	60	48	.	.	PUNCT
dhrp-31	61	1	disclosures	disclosure	NOUN
dhrp-31	61	2	:	:	PUNCT
dhrp-31	61	3	none	none	NOUN
dhrp-31	61	4	orcid	orcid	NOUN
dhrp-31	61	5	:	:	PUNCT
dhrp-31	62	1	caitlin	caitlin	PROPN
dhrp-31	62	2	white	white	PROPN
dhrp-31	62	3	:	:	PUNCT
dhrp-31	62	4	https://orcid.org/0000-00015528-2242	https://orcid.org/0000-00015528-2242	PROPN
dhrp-31	62	5	manish	manish	PROPN
dhrp-31	62	6	singh	singh	PROPN
dhrp-31	62	7	,	,	PUNCT
dhrp-31	62	8	md	md	PROPN
dhrp-31	62	9	,	,	PUNCT
dhrp-31	62	10	facs	facs	PROPN
dhrp-31	62	11	chief	chief	ADJ
dhrp-31	62	12	executive	executive	ADJ
dhrp-31	62	13	officer	officer	NOUN
dhrp-31	62	14	,	,	PUNCT
dhrp-31	62	15	dhr	dhr	PROPN
dhrp-31	62	16	health	health	PROPN
dhrp-31	62	17	,	,	PUNCT
dhrp-31	62	18	5501	5501	NUM
dhrp-31	62	19	s.	s.	PROPN
dhrp-31	62	20	mccoll	mccoll	PROPN
dhrp-31	62	21	road	road	PROPN
dhrp-31	62	22	,	,	PUNCT
dhrp-31	62	23	edinburg	edinburg	PROPN
dhrp-31	62	24	,	,	PUNCT
dhrp-31	62	25	texas	texas	PROPN
dhrp-31	62	26	dhr	dhr	PROPN
dhrp-31	62	27	health	health	PROPN
dhrp-31	62	28	bariatric	bariatric	PROPN
dhrp-31	62	29	&	&	CCONJ
dhrp-31	62	30	metabolic	metabolic	PROPN
dhrp-31	62	31	institute	institute	PROPN
dhrp-31	62	32	,	,	PUNCT
dhrp-31	62	33	5500	5500	NUM
dhrp-31	62	34	raphael	raphael	PROPN
dhrp-31	62	35	drive	drive	PROPN
dhrp-31	62	36	,	,	PUNCT
dhrp-31	62	37	edinburg	edinburg	PROPN
dhrp-31	62	38	,	,	PUNCT
dhrp-31	62	39	tx	tx	PROPN
dhrp-31	62	40	79539	79539	NUM
dhrp-31	62	41	disclosures	disclosure	NOUN
dhrp-31	62	42	:	:	PUNCT
dhrp-31	62	43	none	none	NOUN
dhrp-31	62	44	orcid	orcid	NOUN
dhrp-31	62	45	:	:	PUNCT
dhrp-31	62	46	manish	manish	PROPN
dhrp-31	62	47	singh	singh	PROPN
dhrp-31	62	48	:	:	PUNCT
dhrp-31	62	49	https://orcid.org/0000-00034146-3282	https://orcid.org/0000-00034146-3282	PROPN
dhrp-31	62	50	https://orcid.org/0000-0001-5528-2242	https://orcid.org/0000-0001-5528-2242	VERB
dhrp-31	62	51	https://orcid.org/0000-0001-5528-2242	https://orcid.org/0000-0001-5528-2242	NOUN